Zucaglim M1 Forte Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with Metformin immediate-release preparations. Zucaglim M1 Forte is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately managed with either monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Contraindications include severe renal or hepatic impairment, metabolic acidosis, and hypersensitivity to any component. Caution is advised in patients with cardiovascular disease or risk factors for lactic acidosis. This combination therapy offers a synergistic approach to managing hyperglycemia, optimizing patient outcomes in type 2 diabetes management.